Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. (Nasdaq: PRQR) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing RNA editing therapies. Its updates center on the Axiomer RNA base editing platform and a pipeline of editing oligonucleotides designed to correct or modulate disease-related targets at the RNA level. News coverage on this page reflects company announcements, clinical milestones, financial updates, and scientific presentations related to its programs in liver, CNS, and other genetically defined diseases.
Investors and followers of PRQR can expect news about the progress of AX-0810, ProQR’s lead investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. Recent releases describe the submission and authorization of a Clinical Trial Application, the initiation of a Phase 1 first-in-human study in healthy volunteers in the Netherlands, and early safety and pharmacokinetic observations from the first cohort. Updates also outline plans for target engagement readouts and the future inclusion of a patient cohort in the same trial.
News items also highlight earlier-stage pipeline programs such as AX-2402 for Rett syndrome (MECP2 R270X), AX-2911 for metabolic liver disease including MASH (PNPLA3 I148M), and AX-1412 for cardiovascular disease (B4GALT1). ProQR reports non-clinical proof-of-concept data, development candidate selections, and functional results in disease-relevant models. Financial press releases provide quarterly operating and financial results, cash and cash equivalents, collaboration revenue from Eli Lilly, and comments on cash runway.
Additional PRQR news covers participation in scientific and investor conferences, including ASGCT, the RNA Editing Summit, OTS, TIDES USA, and healthcare investor events. These communications feature presentations on ADAR-mediated RNA editing of NTCP, PNPLA3, and MECP2, as well as platform-focused talks on optimizing editing oligonucleotides for therapeutic use. Bookmark this page to follow ProQR’s disclosed clinical data, pipeline milestones, collaboration developments, and financial reporting as they are released through press announcements and SEC-furnished materials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its participation in several upcoming investor conferences to discuss its innovative RNA therapies using the Axiomer® RNA editing technology platform. Key events include:
- Van Lanschot Kempen Life Sciences Conference – April 26, Amsterdam (1x1 meetings only)
- JMP Securities Life Sciences Conference – May 16, New York (Fireside chat at 12:30 PM EDT)
- Stifel 2023 Tailoring Genes: Genetic Medicines Day – May 30, Virtual (Fireside chat, time TBC)
Details on presentations and webcasts will be available on the company’s website. ProQR is focused on advancing RNA therapies that address both rare and common diseases, utilizing its unique Axiomer® technology for precise RNA editing.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its Annual General Meeting (AGM) of Shareholders scheduled for May 17, 2023, at 16:00 CET, in Amsterdam. Key updates include the nomination of Begoña Carreño and Theresa Heggie to the Supervisory Board, along with Bart Filius for re-election. Notably, Antoine Papiernik will rotate off the Board. Carreño brings over 20 years of experience in pharmaceutical development and strategy from Novartis, while Heggie has a strong background in commercial operations at Alnylam Pharmaceuticals. ProQR focuses on transformative RNA therapies utilizing its proprietary Axiomer® RNA editing technology, aiming to provide innovative treatment options for diseases with unmet needs.
ProQR Therapeutics NV (Nasdaq: PRQR) announced initial pipeline programs focused on liver diseases, introducing AX-0810 targeting NTCP for cholestatic diseases and AX-1412 targeting B4GALT1 for cardiovascular disease. Clinical trials are expected to start in late 2024 or early 2025. The company reported year-end 2022 financials, with a cash reserve of €94.8 million, extended cash runway into mid-2026, and a net loss of €64.9 million. Notable preclinical activity was reported, with up to 50% RNA editing observed in both rodent and non-human primate models, showcasing the Axiomer platform's potential.
ProQR Therapeutics (Nasdaq: PRQR) recently defended its key patent for the Axiomer® RNA editing platform against two oppositions filed in February 2021. The European Patent Office ruled in favor of ProQR after a public hearing held on March 7 and 8, 2023. This patent is crucial for ProQR’s intellectual property, which includes 22 patents across 10 families. The company emphasizes that its robust patent estate positions it as a leader in the field of RNA editing technology. ProQR aims to develop transformative therapies for diseases using its innovations in RNA editing.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced key presentations at upcoming conferences to showcase its Axiomer® RNA editing platform. Events include the Oligonucleotide and Precision Therapeutics (OPT) Congress on March 14, 2023, where CSO Gerard Platenburg will discuss therapeutic potentials of Editing Oligonucleotides (EONs). Additionally, at the RNA Leaders Europe Congress on March 16, 2023, CEO Daniel A. de Boer will explore the transformative capabilities of Axiomer. The RNA Editing Gordon Research Conference on March 23, 2023, will feature Platenburg's insights into addressing liver disorders with Axiomer. This innovative platform aims to revolutionize RNA therapies for various unmet medical needs.
FAQ
What is the current stock price of Proqr Therapeuti (PRQR)?
What is the market cap of Proqr Therapeuti (PRQR)?
